It provides low variability in blood glucose levels and a lower risk of overall, nocturnal and severe hypoglycaemia vs insulin glargine U100. On occasions when administration at the same time of day is not possible, Tresiba ® allows for flexibility in day-to-day dosing time with a minimum of eight hours between injections. Tresiba ® received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally.